Prevention and treatment of amyloidogenic diseases
First Claim
1. A method of therapeutically treating a human patient having amyloid A amyloidosis comprising administering to the patient an effective dosage of an antibody or fragment thereof directed to and that specifically binds to an amyloidogenic portion of amyloid A protein, thereby effecting a passive immune response in the patient, to thereby treat amyloid A amyloidosis.
8 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer'"'"'s disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.
88 Citations
22 Claims
- 1. A method of therapeutically treating a human patient having amyloid A amyloidosis comprising administering to the patient an effective dosage of an antibody or fragment thereof directed to and that specifically binds to an amyloidogenic portion of amyloid A protein, thereby effecting a passive immune response in the patient, to thereby treat amyloid A amyloidosis.
- 12. A method of reducing risk or delaying onset of amyloid A amyloidosis in a human patient at risk of amyloid A amyloidosis comprising administering to the patient an effective dosage of an antibody or fragment thereof directed to and that specifically binds to an amyloidogenic portion of amyloid A protein, thereby effecting a passive immune response in the patient, to thereby effect prophylaxis of amyloid A amyloidosis.
Specification